Christopher Richard Anzalone Sells 24,338 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Christopher Richard Anzalone sold 24,338 shares of the business’s stock in a transaction dated Wednesday, October 25th. The stock was sold at an average price of $24.21, for a total transaction of $589,222.98. Following the completion of the transaction, the chief executive officer now directly owns 3,737,000 shares of the company’s stock, valued at $90,472,770. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Christopher Richard Anzalone also recently made the following trade(s):

• On Monday, September 18th, Christopher Richard Anzalone sold 57,755 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $28.12, for a total transaction of $1,624,070.60.

Arrowhead Pharmaceuticals Stock Down 3.3 %

Arrowhead Pharmaceuticals stock opened at $23.60 on Friday. The stock has a market capitalization of $2.53 billion, a PE ratio of -13.80 and a beta of 1.00. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $23.09 and a twelve month high of $42.48. The company has a 50 day moving average of $26.97 and a 200-day moving average of $31.84.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.38). The business had revenue of $15.83 million during the quarter, compared to the consensus estimate of $45.42 million. Arrowhead Pharmaceuticals had a negative return on equity of 42.79% and a negative net margin of 69.38%. The business’s revenue for the quarter was down 51.2% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.68) EPS. Equities analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -1.67 EPS for the current fiscal year.

Institutional Trading of Arrowhead Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the business. BlackRock Inc. lifted its position in shares of Arrowhead Pharmaceuticals by 0.8% in the second quarter. BlackRock Inc. now owns 12,811,158 shares of the biotechnology company’s stock worth $456,846,000 after purchasing an additional 100,357 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Arrowhead Pharmaceuticals by 0.8% in the third quarter. Vanguard Group Inc. now owns 10,145,990 shares of the biotechnology company’s stock worth $335,325,000 after purchasing an additional 76,653 shares in the last quarter. State Street Corp lifted its position in shares of Arrowhead Pharmaceuticals by 19.2% in the second quarter. State Street Corp now owns 5,582,746 shares of the biotechnology company’s stock worth $196,568,000 after purchasing an additional 900,791 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Arrowhead Pharmaceuticals by 3.2% in the first quarter. JPMorgan Chase & Co. now owns 2,909,965 shares of the biotechnology company’s stock worth $73,913,000 after purchasing an additional 89,143 shares in the last quarter. Finally, Alliancebernstein L.P. raised its position in Arrowhead Pharmaceuticals by 4.8% during the fourth quarter. Alliancebernstein L.P. now owns 2,584,693 shares of the biotechnology company’s stock worth $104,835,000 after acquiring an additional 117,633 shares in the last quarter. Institutional investors own 65.98% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on ARWR. Royal Bank of Canada reiterated an “outperform” rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, August 8th. B. Riley reiterated a “buy” rating and set a $55.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Thursday, July 20th. Citigroup started coverage on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, September 19th. They set a “neutral” rating and a $33.00 price target for the company. StockNews.com upgraded shares of Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, October 7th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $47.00 price objective (down previously from $79.00) on shares of Arrowhead Pharmaceuticals in a report on Tuesday, August 8th. Six equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat, Arrowhead Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $54.53.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis.